TA: Here are some comments on your last post.
Good investing!
BigKNY3
TA <<WARNING, WARNING, WARNING: DON'T BUY THIS STOCK!!!>>
BigKNY3 Comments: I really enjoyed your humor!
TA:<< FORTUNE : "The Selling of Impotence ", or " more hype still !!!( The DEFINITIVE article on IMPOTENCE , TA's opinion >>
BigKNY3 Comments: Very surprised that you would consider this 7 page article "the DEFINITIVE article on IMPOTENCE". The transurethral properties of MUSE are never described. Moreover, MUSE is only mentioned in the following two paragraphs:
"The expanded definition of ED has also led to wild estimates of the
future incidence of the condition. Last fall the American Foundation for Urologic Disease launched a national "impotence awareness" campaign funded by Vivus, the maker of a recently approved impotence treatment called Muse. The campaign began with a press release citing a staggering statistic: Due to the aging of the population, it stated, some 47 million U.S. men are expected to suffer from ED by 2000. That might seem a bit strange: There are only about 52 million American men over 40 today. Confronted with the math, a spokeswoman for the foundation, an offshoot of the American Urological Association, says the high estimate may have been a mistake."
"That prospect has brought renewed glow to small players that stand to
capture a piece of the huge ED pie. Vivus recently launched a national
advertising campaign for Muse with an estimated budget of more than $5
million. At press time the company's stock price had risen some 35% from its year-end low."
TA:<< I got hold of BigKNY3's " last word", " a definitive book " on Phosphodiesterase inhibitors"- book, by Christian Schudt. Hmmmm...very interesting... I am in the process of reading it and will report to this thread. SO FAR THERE IS NO MENTION OF Sildenafil in this " all inclusive, up to date 217 page book on PDEs and PDE inhibitors;>>
BigKNY3 Comments: This is the definitive textbook published on PDE Inhibitors....that is currently available. It is definitely not the "last word"...TA's words not mine. The book was published in 1996 and probably written in 1995. Accordingly, it would be very difficult for the authors to included information on PDE-V inhibitors and sildenafil that is now known since 1996 and the results of clinical studies from 1996-1998 that will be published in the near future..... A good example of the disadvantages of print over the Internet.
However, this textbook should really add to your knowledge of PDE Inhibitors. To save you some time, here is the relevant section on PDE-V Inhibitors and the reference to sildenafil (obviously written before any Phase II or Phase III results were known) (p131):
"Another area in which NO plays a key role is penile erection. Rafjer et al (1992) have shown that the non-adrenergic, non-cholinergic (NANC) transmitter is NO and that vascular endothelial NO in the corpus cavernosum elicits penile erection via vasodilation. Impotence may be related to decrease releases of NO. Both NO donors and PDE-V inhibitors can reverse impotence by cGMP-related vasodilation in preclinical models. In addition, some pharmaceutical companies are purportedly having some success in treating impotence with PDE-V inhibitors in early clinical trials."
"More recently, three new chemical series of inhibitors have been described which possess nanomolar potency for inhibition of PDEV. The first series (is) described in a patent by Pfizer." |
